← Centessa Pharmaceuticals plc
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $6.9m |
$0
-100.00%
|
$15.0m |
$0
-100.00%
|
|
| Net Interest Income | — | — | ($7.0m) |
$570k
+108.10%
|
$3.9m
+588.77%
|
$9.1m
+130.97%
|
$6.5m
-28.74%
|
|
| Research and development | $9.3m | $95.7m | $155.1m | $124.4m | $150.2m | $172.2m | $198.7m | |
| General and administrative | $1.1m | $42.9m | $55.2m | $53.7m | $50.8m | $50.5m | $58.0m | |
| Restructuring And Mergern Acquisition | — | — | $2.0m | $0 | — | — | — | |
| Operating Lease, Expense | — | — | — | $1.6m | — | — | — | |
| Operating expenses: | ||||||||
| Loss from operations | ($10.4m) |
($374.1m)
-3483.18%
|
($212.3m)
+43.26%
|
($171.3m)
+19.31%
|
($201.1m)
-17.38%
|
($207.7m)
-3.30%
|
— | |
| Operating Income (Loss) | ($10.4m) |
($374.1m)
-3483.18%
|
($212.3m)
+43.26%
|
($171.3m)
+19.31%
|
($201.1m)
-17.38%
|
($207.7m)
-3.30%
|
($256.7m)
-23.59%
|
|
| Interest income | — | — | $244k | $10.5m | $14.0m | $20.5m | $17.8m | |
| Net Non Operating Interest Income Expense | — | — | ($7.0m) | $570k | $3.9m | $9.1m | $6.5m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | ($3.6m) | ($2.8m) | $800k | ($1.8m) | $2.9m | — | |
| Other Nonoperating Income (Expense) | $155k | ($4.4m) | $2.3m | ($5.4m) | ($1.7m) | $2.9m | — | |
| Interest Expense (non-operating) | — | — | $7.3m | $9.9m | $10.1m | $11.5m | $11.3m | |
| Other Income Expense | — | — | $362k | ($5.4m) | ($35.8m) | $2.9m | $860k | |
| Interest Income (Expense), Nonoperating, Net | ($68k) | ($1.2m) | ($7.0m) | $10.5m | — | — | $17.8m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | ($173.5m) | ($187.6m) | ($248.6m) | ($218.0m) | ($249.4m) | |
| Loss before income taxes | ($10.7m) | ($381.0m) | ($217.0m) | ($176.1m) | ($232.9m) | ($195.7m) | — | |
| Pre-Tax Income | ($10.7m) | ($381.0m) | ($217.0m) | ($176.1m) | ($232.9m) | ($195.7m) | ($249.4m) | |
| Income tax expense | $0 | $114k | ($747k) | ($25.1m) | $2.8m | $1.8m | $1.3m | |
| Net loss | ($10.7m) | ($381.1m) | ($216.2m) | ($151.1m) | ($235.8m) | ($197.5m) | — | |
| Reclassification adjustment for realized net gain on available for sale marketable securities included in net loss, net of tax of $0.8 million in 2025 and $0.4 million in 2024 | — | — | — | — | ($1.3m) | ($2.8m) | — | |
| Net Income From Continuing And Discontinued Operation | ($10.7m) | ($381.1m) | ($216.2m) | ($151.1m) | ($235.8m) | ($197.5m) | ($250.6m) | |
| Earnings Per Share, Basic | — | ($5.07) | ($2.31) | ($1.57) | ($2.06) | ($1.46) | ($1.78) | |
| Earnings Per Share, Diluted | — | ($5.07) | ($2.31) | ($1.57) | ($2.06) | ($1.46) | ($1.78) | |
| Preferred Stock, Dividends Per Share, Declared | — | $0.00 | ($2.31) | ($1.57) | ($2.06) | ($1.46) | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | 75.2m | 93.4m | 96.2m | 114.5m | 135.7m | 140.8m | |
| Weighted average ordinary shares outstanding - basic (in shares) | — | 75.2m | 93.4m | 96.2m | 114.5m | 135.7m | — | |
| Weighted average ordinary shares outstanding - diluted (in shares) | — | 75.2m | 93.4m | 96.2m | 114.5m | 135.7m | — | |
| Basic Average Shares | — | 75.2m | $93.4m | $96.2m | $114.5m | $135.7m | $140.8m | |
| Diluted Average Shares | — | 75.2m | $93.4m | $96.2m | $114.5m | $135.7m | $140.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 75.2m | 93.4m | 96.2m | 114.5m | 135.7m | 140.8m | |
| Additional Financial Items | ||||||||
| Capitalized Computer Software, Amortization | — | — | — | $500k | $600k | $600k | — | |
| Loss on extinguishment of debt | — | — | — | $0 | ($34.1m) | $0 | — | |
| Foreign currency translation adjustments | ($240k) | $778k | ($2.2m) | $1.7m | $1.2m | $1.0m | — | |
| Unrealized gain on available for sale securities, net of tax of $0.1 million in 2025 and $0.8 million in 2024 | — | — | — | — | $2.8m | $243k | — | |
| Other comprehensive (loss) income | — | — | — | $3.0m | $2.7m | ($1.5m) | — | |
| Diluted EPS | — | ($5.07) | ($2.31) | ($1.57) | ($2.06) | ($1.46) | ($1.78) | |
| Diluted NI Availto Com Stockholders | ($10.7m) | ($381.1m) | ($216.2m) | ($151.1m) | ($235.8m) | ($197.5m) | ($250.6m) | |
| Normalized EBITDA | — | — | ($207.6m) | ($165.4m) | ($187.8m) | ($183.3m) | ($237.1m) | |
| Normalized Income | — | — | ($214.2m) | ($151.1m) | ($210.2m) | ($197.5m) | ($250.6m) | |
| Other Gand A | — | — | $29.3m | $26.1m | $19.9m | $21.1m | — | |
| Reconciled Depreciation | — | — | $131k | $810k | $942k | $921k | $943k | |
| Salaries And Wages | — | — | $25.9m | $27.6m | $30.9m | $29.4m | $33.9m | |
| Selling General And Administration | $1.1m | $42.9m | $55.2m | $53.7m | $50.8m | $50.5m | — | |
| Special Income Charges | — | — | ($2.0m) | $0 | ($34.1m) | $0 | $0 | |
| Tax Effect Of Unusual Items | — | — | ($7k) | $0 | ($8.5m) | $0 | $0 | |
| Tax Provision | $0 | $114k | ($747k) | ($25.1m) | $2.8m | $1.8m | $1.3m | |
| Tax Rate For Calcs | — | — | $0 | $0 | $0 | $0 | $0 | |
| Operating Expense | — | — | $210.3m | $178.1m | $201.1m | $222.7m | $256.7m | |
| Total comprehensive (loss) income | ($10.9m) | ($380.3m) | ($218.4m) | ($148.1m) | ($233.0m) | ($199.0m) | — | |
| Total Unusual Items | — | — | ($2.0m) | $0 | ($34.1m) | $0 | $0 | |
| Total Expenses | — | — | $210.3m | $178.1m | $201.1m | $222.7m | $256.7m |